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Abstract. Synapse loss occurs early in Alzheimer’s disease (AD) and is considered the best pathological correlate of cognitive
decline. Ephrins and Eph receptors are involved in regulation of excitatory neurotransmission and play a role in cytoskeleton
remodeling. We asked whether alterations in Eph receptors could underlie cognitive impairment in an AD mouse model
overexpressing human amyloid-β protein precursor (hAβPP) with familial mutations (hAβPPswe-ind mice). We found that
EphA4 and EphB2 receptors were reduced in the hippocampus before the development of impaired object recognition and spatial
memory. Similar results were obtained in another line of transgenic AβPP mice, Tg2576. A reduction in Eph receptor levels
was also found in postmortem hippocampal tissue from patients with incipient AD. At the time of onset of memory decline
in hAβPPswe-ind mice, no change in surface expression of AMPA or NMDA receptor subunits was apparent, but we found
changes in Eph-receptor downstream signaling, in particular a decrease in membrane-associated phospho-cofilin levels that may
cause cytoskeletal changes and disrupted synaptic activity. Consistent with this finding, Eph receptor activation in cell culture
increased phospho-cofilin levels. The results suggest that alterations in Eph receptors may play a role in synaptic dysfunction in
the hippocampus leading to cognitive impairment in a model of AD.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurode-
generative disorder characterized by two histopatho-
logical hallmarks, the amyloid plaques, mainly com-
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plona, Spain. Tel./Fax: +34 948 194700/15, E-mail: jdelrio@unav.
es.
posed of the amyloid-β (Aβ) peptide, and the neurofib-
rillary tangles, comprised of hyperphosphorylated pro-
tein tau [1]. Yet, it is now well documented that the best
neuropathological correlate of cognitive decline in AD
patients is a severe synapse loss in the hippocampus
and other brain regions. In addition, the remaining den-
drites of affected neurons show a dystrophic pattern [2].
Accordingly, AD is now considered as a synaptopathy.
Several findings in brains of AD patients and trans-
genic animal models suggest that synaptic function
is compromised prior to physical degeneration of the
ISSN 1387-2877/09/$17.00  2009 – IOS Press and the authors. All rights reserved
774 A.M. Simo´n et al. / Eph Receptors in Alzheimer’s Disease
synapses [3,4]. The high plasticity of synapses is es-
sential for numerous events associated with cognition.
Of particular relevance for memory consolidation is the
increase in strength of excitatory inputs to the post-
synaptic neuron and the remodeling of cytoskeleton
(e.g., [5]). NMDA and AMPA glutamate receptor sub-
types are the primary mediators of excitatory synaptic
transmission in the hippocampus. Both of them are es-
sential for LTP induction and maintenance respectively
and are required for spatial learning and memory [6].
Changes in the cytoskeleton also have a crucial role in
synaptic plasticity, and synaptic strength is correlated
with the size of dendritic spines and their capacity of
remodeling [7].
Among signals that regulate excitatory synaptic
strength and cytoskeleton architecture, ephrins and
their receptors play a crucial role [8]. Ephrins and Eph
receptors are cell-surface proteins implicated in devel-
opmental events such as tissue patterning, angiogen-
esis, and axon guidance [9,10], and in regulation of
synapse function and plasticity in the adult brain, par-
ticularly in the hippocampus [11,12]. Eph receptors
form the largest family of receptor tyrosine-kinases and
14 different members have been identified at present
in mammals (EphA1-8 and EphA10, EphB1-4 and
EphB6) [13]. Eph receptors maintain and stabilize
synaptic structure through activation of small G pro-
teins, RhoA, Rac, and Cdc42 among others, and down-
stream effectors such as cofilin [14,15], and also regu-
late glutamatergic neurotransmission through modula-
tion of NMDA and AMPA receptor function [16]. The
critical role of Eph receptor subtypes in synaptic plas-
ticity has been demonstrated in numerous studies [17–
19]. EphA4 and EphB2 are the two Eph receptors most
intensively studied in the adult brain, where they have
been detected in many regions, especially in the neocor-
tex and hippocampus [20,21]. The multiple pathways
involved in the regulation of synaptic function after Eph
receptor activation remain to be fully elucidated.
In transgenic mice overexpressing human amyloid-
β protein precursor (hAβPP), levels of a 56-kDa
oligomeric soluble species of Aβ, but not of insoluble
Aβ, correlate with memory impairment [22], perhaps
through an interaction with glutamate receptors [23].
Indeed, some reports have shown alterations in AM-
PA and NMDA receptors in postsynaptic hippocampal
membranes of brains from both AD patients [24] and
cultured neurons of AβPP transgenic mice [25,26]. Be-
cause of the critical role of Eph receptors in synaptic
plasticity, we explored the possibility that Eph receptor
alterations could be correlated with cognitive deficits
in these mice so we analyzed the time-course of the ex-
pression of EphA4 and EphB2 receptors, which present
an overlapping distribution in the hippocampus [20],
as well as AMPA and NMDA receptor subunit levels,
looking for a correlation with the progression of cogni-
tive impairment. We also sought other related molecu-
lar changes downstream of ephrin-Eph receptor signal-
ing, such as p21-activated kinase (PAK), LIM-kinase
(LIMK), and in particular alterations in the activity of
cofilin, a protein of the cofilin/actin depolymerization
factor family that binds and depolymerizes actin fila-
ments [27] and is consequently implicated in the plas-
ticity of dendritic spines. Many recent studies [28–30]
have highlighted the role of altered cofilin activity as an
important factor contributing to neuronal degeneration
in AD.
MATERIALS AND METHODS
Mice
Transgenic hAβPPswe-ind mice overexpressing
hAβPP with the Swedish (K670N/M671L) and In-
diana (V717F) familial AD mutations under control
of the PDGF promoter were used in this study (J20
line) [31]. The mice were on an inbred C57BL/6J ge-
netic background. Some experiments were also per-
formed with Tg2576 mice (Taconic, NY, USA) that
overexpress hAβPP with the double Swedish muta-
tion [32]. Animals were housed four-five per cage
with free access to food and water and maintained
in a temperature-controlled environment on a 12 h
light/dark cycle. All procedures were carried out in
accordance with European and Spanish regulations
(86/609/CEE; RD1201/2005). This study was ap-
proved by the Ethical Committee of the University of
Navarra (no. 018/05).
Postmortem human brain tissue
Frozen postmortem human brain tissue was obtained
from the Neurological Tissue Bank of Navarra Hos-
pital. Hippocampal sections from three AD cases
and three age-matched non-demented controls were
analyzed. All cases had been neuropathologically
confirmed, using conventional histopathological tech-
niques, and diagnosis performed using the CERAD
criteria. Neuropathological staging of neurofibrillary
changes (I–VI) was performed according to Braak and
Braak [33]. The three AD cases were assigned to Braak
stage II/III (CERAD stage A).
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Cell cultures
Primary neuronal cultures were prepared from hip-
pocampi of embryonic day 16 (E16) hAβPPswe-ind
mice and non-transgenic littermates. One pup corre-
sponded to one set of cultures, and genotyping was per-
formed using the cerebellum. After mechanical dis-
sociation, cells were cultured on poly-L-lysine coat-
ed plates maintained in Neurobasal medium (Invit-
rogen) containing 2% B27 supplement (Invitrogen),
1% GlutaMAXTM I (Invitrogen), and 1% penicillin
(10,000 units/ml)/streptomycin (10,000 µg/ml) (Invit-
rogen) at 37◦C in a humidified 5% CO2 atmosphere.
After 20 days in vitro (DIV), whole-cell lysates were
prepared as below described.
Human neuroblastoma SH-SY5Y cells were grown
in Dulbecco’s modified Eagle medium (DMEM) (Sig-
ma) supplemented with 10% fetal bovine serum (Sig-
ma), 1% GlutaMAXTM I (Invitrogen), and 1% peni-
cillin (10,000 units/ml)/streptomycin (10,000 µg/ml)
(Invitrogen) at 37◦C in a humidified 5% CO2 atmo-
sphere. Serum-starved SH-SY5Y cells were treated
with 4 µg/ml preclustered human ephrinB3/Fc (R&D
Systems) at 37◦C for 15 min. Preclustering of the
ephrin ligand/Fc chimera was achieved by incubation
with anti-human Fc antibodies (Jackson ImmunoRe-
search Labs) at a 2:1 ratio (w/w) for 1 h at 4◦C
(e.g., [34]). Control cells were treated with anti-Fc an-
tibodies only. After cell stimulation, whole-cell lysates
were prepared.
Production of protein extracts
Total tissue lysates from mouse or human brain were
obtained by homogenizing the hippocampus in ice-cold
RIPA buffer (50 mM Tris-HCl pH 7.4, 0.25% sodi-
um deoxycholate (DOC), 1% Nonidet P-40, 150 mM
NaCl, 1 mM EDTA, 1 mM PMSF, 1 µg/ml leupeptin,
1 µg/ml aprotinin, 1 mM Na3VO4, 1 mM NaF), cen-
trifuged at 14,000 g, 4◦C for 20 min and the supernatant
was aliquoted and frozen at −80◦C. The same method
was used for obtaining whole-cell lysates. To obtain
the membrane-enriched protein fraction (P2 membrane
proteins), a previously described method [35] was used.
The hippocampus was homogenized in ice-cold Tris-
EDTA buffer (10 mM Tris-HCl and 5 mM EDTA, pH
7.4), containing 320 mM sucrose and the protease and
phosphatase inhibitors previously described. The tis-
sue homogenate was centrifuged at 700 g for 10 min.
The supernatant was centrifuged again at 37,000 g for
40 min at 4◦C. The pellet (P2) was resuspended in
10 mM Tris-HCl buffer (pH 7.4), containing the en-
zyme inhibitor mixture described above. In both cases,
protein concentration was determined (Bio-Rad Brad-
ford assay) and aliquots were stored at −80◦C until
used. For Western blot analysis, aliquots of the P2
membrane fraction were solubilized in non-denaturing
conditions by adding 0.1 vol of 10% DOC in 500 mM
Tris-HCl buffer (pH 9). The samples were incubated
for 30 min at 36◦C and diluted by adding 0.1 volume
of 500 mM Tris-HCl (pH 9)/1% Triton X-100. Af-
ter a centrifugation at 37,000 g for 10 min at 4 ◦C, the
supernatant was frozen at −80◦C.
Western blotting
Protein samples were mixed with an equal vol-
ume of 2x Laemmli sample buffer, resolved on-
to SDS-polyacrylamide gels and transferred to nitro-
cellulose membrane (Hybond ECL, Amersham Bio-
sciences) using a Trans-Blot SD semidry system
(Bio-Rad) for 30 min at 12 V. The membranes were
blocked with 5% milk, 0.05% Tween-20 in PBS
or TBS followed by overnight incubation with the
following primary antibodies: goat polyclonal anti-
EphA4 (0.2 µg/ml, R&D Systems), goat polyclonal
anti-EphB2 (0.2 µg/ml, R&D Systems), rabbit poly-
clonal anti-PAK1/2/3 (1:2000, Cell Signaling), rabbit
polyclonal anti-phospho-PAK1/2/3 (Ser141) (1:2000,
Invitrogen), rabbit polyclonal anti-LIMK1 (1:1000,
Santa Cruz), rabbit polyclonal anti-phospho-LIMK1
(Thr508)/LIMK2 (Thr505) (1:1000, Cell Signaling),
rabbit polyclonal anti-cofilin (1:1000, Chemicon), rab-
bit polyclonal anti-phospho-cofilin (Ser3) (1:1000, Cell
Signaling), rabbit polyclonal anti-GluR1 (0.2 µg/ml,
Chemicon), rabbit polyclonal anti-GluR2/3 (0.1µg/ml,
Chemicon), rabbit polyclonal anti-NR1 (1:1000, Up-
state), rabbit polyclonal anti-NR2A (1:1000, Upstate),
rabbit polyclonal anti-NR2B (1:1000, Upstate), and
mouse monoclonal anti-β-actin (1:100000, Sigma),
in the corresponding buffer. Following two washes
in PBS/Tween-20 or TBS/Tween20 and one PBS or
TBS alone, immunolabeled protein bands were de-
tected by using HRP-conjugated anti-rabbit or anti-
mouse antibody (Dako; dilution 1:1500) following
an enhanced chemiluminiscence system (ECL Amer-
sham Biosciences), and autoradiographic exposure
to HyperfilmTMECL (Amersham Biosciences). The
quantification of signals was performed using Scion
Image software (Scion Corporation).
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Behavioral procedures
Object recognition test. The apparatus consisted of
a dark open box (50 × 35 × 50 cm high), illuminated
by a 60 W lamp suspended 120 cm above the box. The
different objects consisted in general in red rectangular
prisms (2 × 2 × 8 cm high) and white pyramids (5 ×
5 × 5 cm high). These objects could not be displaced
by the mice. In the week preceding testing, the animals
were handled daily and adapted to the room in which
the behavioral procedures were performed. The ob-
ject recognition test was performed as described else-
where [36,37] with minor modifications. One h before
testing, the mice were allowed to explore the appara-
tus without objects for 5 min. After habituation, two
familiarization sessions were given (T1 and T2 10 min
apart), in which the animals were left to explore for
10 min two identical objects (red prisms) that were
placed in opposite sides of the apparatus 10 cm from
the side wall. The choice trial (T3), in which memory
retention was tested, was given 24 h after T2. In this
session, two objects were presented, one of the prisms
used in familiarization session (T1 and T2) and other
different in shape and color; therefore the mice were
re-exposed to a familiar (F) and a novel object (N). Ex-
ploration was defined as directing the nose to an object
at a distance2 cm and/or touching the object with the
nose.
To avoid the presence of olfactory trails, the appara-
tus and the objects were thoroughly cleaned after each
trial. The time spent by the animals in exploring each
object was recorded manually by using a stopwatch.
The reaction to a novel object during T3 was measured
by calculating the discrimination index (DI): time spent
exploring the novel object over total exploration time.
Consequently, a ratio of 0.5 reflects equal exploration of
the familiar and the novel object, indicating no learning
retention
Morris water maze. Groups of transgenic hAβPP
swe-ind mice and non transgenic littermates (n = 12),
underwent spatial reference learning and memory in
the Morris water maze (MWM) test, a hippocampus-
dependent learning task. The maze was a circular tank
(diameter 1.45 m) filled with water at 20◦C. Mice un-
derwent visible-platform training for three consecutive
days (8 trials/day), and were allowed to swim to a raised
platform located above the water. Hidden-platform
training was conducted over 9 consecutive days (4 tri-
als/day). Mice had 60 s to find a hidden platform sub-
merged 1 cm beneath the surface of the water and invis-
ible to the mice while swimming. Several large visual
cues were placed in the room to guide the mice to the
hidden platform. Mice failing to reach the platform
were guided onto it. All the animals were allowed to
rest on the platform for 20 s and then removed from the
platform and returned to their home cage. At the be-
ginning of 4th, 7th, and 9th day of the task, a probe trial
in which the platform was removed from the pool was
conducted, and the mice were permitted to search the
platform for 60 s. All trials were monitored by a camera
using an HVS water maze program for analyses of es-
cape latencies and percent time spent in each quadrant
of the pool during probe trials (analysis program Etho-
vision, Wageningen, The Netherlands). Mice that were
unable to reach the visible-platform or mice exhibit-
ing abnormal swimming patterns or persistent floating
were excluded from data analyses.
Statistical analysis
Compiled data were expressed as means ± SEM.
Statistical analysis was assessed with SPSS version
11.5 (SPSS. Inc. Chicago, IL) using the parametric
Student’s t-test or the non-parametric Mann-Whitney
U-test to compare two independent groups. A level
of significance was set at P < 0.05 for comparative
measurement throughout the study.
RESULTS
EphA4 and EphB2 receptor protein in transgenic
AβPP mice
We analyzed EphA4 and EphB2 receptor protein lev-
els in hipppocampal lysates by immunoblotting. A re-
duction of EphA4 levels was apparent in whole-cell
lysates of hAβPPswe-ind mice at very early stages,∼40% at 2 months and ∼20% at 4 months, and also
in 8-month-old animals (Fig. 1A). EphB2 receptor pro-
tein levels were markedly reduced, by∼40%, in tissue
lysates of 2-month-old hAβPPswe-ind mice (Fig. 1B).
In 4- and 8-month-old hAβPPswe-ind mice, no signifi-
cant change was found in EphB2 receptor protein levels
in hippocampal extracts (Fig. 1B).
It appeared of interest to extend these experiments
to another line of transgenic AβPP mice. In 5-month-
old Tg2576 mice, EphA4 and EphB2 receptor protein
levels were reduced by ∼38% and 25% respectively
(Fig. 2). Spatial memory was not impaired in Tg2576
mice until 4–5 months later (not shown).
A reduction of EphA4 and EphB2 receptor protein
levels was also found in primary hippocampal cultures
obtained from embryonic (E16) hAβPPswe-ind trans-
genic mice maintained 20 days in culture (Fig. 3).
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Fig. 1. EphA4 (A) and EphB2 (B) receptor protein levels quantified by Western blot in tissue lysates from the hippocampus of non-transgenic
(Non-Tg) and transgenic hAβPPswe-ind mice. Values, means ± S.E.M. (n = 5–7), normalized according to β-actin levels, are expressed as
percentage of optical density (OD) of the corresponding Non-Tg mice. All experiments were performed in triplicate. **P< 0.01; ***P< 0.001
vs. non-transgenic mice (Student’s t test).
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Fig. 2. EphA4 and EphB2 receptor protein levels quantified by Western blot in tissue lysates from the hippocampus of 5-month-old non-transgenic
(Non-Tg) and transgenic Tg2576 mice. Values, means ± S.E.M. (n = 5), normalized according to β-actin levels, are expressed as percentage
of optical density (OD) of the corresponding Non-Tg mice. All experiments were performed in triplicate. *P< 0.05 vs. non-transgenic mice
(Student’s t test).
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Fig. 3. EphA4 and EphB2 receptor protein levels quantified by Western blot in cell homogenates from primary hippocampal cultures at 20
DIV obtained from embryonic (E16) mice of non-transgenic (Non-Tg) and transgenic hAβPPswe-ind line. Values, means ± S.E.M. (n =
5), are normalized according to β-actin levels and expressed as percentage of optical density (OD) of the corresponding Non-Tg cultures. All
experiments were performed in triplicate. *P< 0.05 vs. non-transgenic cultures (Student’s t test).
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Fig. 4. EphA4 (A) and EphB2 (B) receptor protein levels quantified by Western blot in tissue lysates from the hippocampus of Alzheimer’s
disease (AD) patients with incipient disease (Braak stage II-III, n = 3), and the corresponding controls (n = 3). Values, means ± S.E.M.,
normalized according to β-actin levels, are expressed as percentage of optical density (OD). All experiments were performed in triplicate *P<
0.05; **P< 0.01 vs. controls (Mann Whitney U-test).
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Fig. 5. p-PAK/PAK (A), p-LIMK/LIMK (B) and p-Cofilin/Cofilin (C) ratios in membrane preparations from the hippocampus of non-transgenic
(Non-Tg) and transgenic hAβPPswe-ind mice at 2 and 4 months of age. Values, means± S.E.M. (n = 6), are expressed as percentage of optical
density (OD) of Non-Tg mice. All experiments were performed in triplicate. *P<0.05; **P<0.01 vs. non-transgenic mice (Student’s t test).
EphA4 and EphB2 receptors in postmortem brain
tissue from AD patients
Given that EphA4 and EphB2 receptor levels were
reduced in transgenic hAβPP mice, we also measured
receptor levels in hippocampal tissue from AD patients.
This study included the analysis of hippocampus from
patients with an incipient AD (Braak stages II/III) and
from the corresponding age-matched controls. Inter-
estingly, in keeping with the early changes observed in
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transgenic AβPP mice, we found a significant decrease
in protein levels of both Eph receptors in the hippocam-
pus from patients at an incipient stage of the disease
(∼20% in EphA4 and∼35% in EphB2 receptor protein
levels) (Fig. 4).
PAK, LIM-kinase and cofilin levels and activity in
hAβPPswe-ind mice
As we found lower Eph receptor levels in young
hAβPPswe-ind mice, we hypothesized that signal-
ing downstream these receptors could be down-
regulated. We then determined the levels and activa-
tion state of three molecules regulated by Eph signal-
ing in hippocampal extracts from 2- and 4-month-old
hAβPPswe-ind mice. Cofilin activity is regulated by
kinases such as LIM-kinase 1/2, which in turn is regu-
lated by PAK [38,39].
In membrane preparations from the hippocampus,
both phospho-PAK and phospho-LIMK levels, the ac-
tive forms of the enzymes, were reduced in 2 month- but
not in 4 month-old mice (Fig. 5A,B). In the same prepa-
rations, we found that the decrease in phospho-cofilin
levels, the inactive form, did not reach statistical signifi-
cance in 2-month-old-mice. In 4 month-old mice, how-
ever, p-cofilin levels were markedly reduced (Fig. 5C).
In all cases, the levels of the non-phosphorylated pro-
teins were not significantly modified (Fig. 5). Studies
performed on whole-cell lysates only revealed a slight
non-significant tendency to increase in the p-PAK/PAK
and p-LIMK/LIMK ratios in 2 month-old mice, along
with a lack of change in p-cofilin/cofilin levels (not
shown).
Effect of Eph receptor activation on phospho-cofilin
levels in cell culture
Because reduced phospho-cofilin levels might be at-
tributed to the reduced expression of Eph receptors in
transgenic AβPP mice, we determined whether Eph re-
ceptor activation could increase phospho-cofilin levels
in an in vitro assay. To activate Eph receptors, the lig-
and ephrinB3-Fc, that activates EphB(1–3) and EphA4
receptors was used. Exposure of a human neuroblas-
toma cell line to this ligand for 15 min produced a vast
increase in phospho-cofilin levels (Fig. 6).
AMPA and NMDA receptor subunits in
hAβPPswe-ind mice
Analysis by Western blot of AMPA receptor subunit
GluR1 in solubilized membrane preparation revealed
no modifications neither in 2 month- nor in 4 month-old
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Fig. 6. Effect of ephrinB3-Fc on p-Cofilin/Cofilin ratio in lysates
from cultured SH-SY5Y cells exposed to the the ligand (4 µg/ml)
for 15 min. Data are means ± S.E.M. (n = 3–4). *P<0.05 vs. Fc
controls (Student’s t test).
animals versus the non-transgenic mice. In 8 month-
old mice, a significant decrease in GluR1 membrane
levels, ∼40% (P < 0.01), was found in the transgenic
mice versus the non-transgenic controls (Fig. 7A). No
changes in GluR2/3 membrane levels were detected at
any time (Fig. 7B).
We also measured NMDA receptor NR1, NR2A and
NR2B subunits in 8-month-old hAβPPswe-ind trans-
genic mice. No change was observed in the levels of
any subunit in membrane enriched fractions (Fig. 8).
Behavioral studies
Object recognition. Recognition memory was test-
ed at early and late stages (2, 4, and 8 months) in
hAβPPswe-ind transgenic mice. Impaired recogni-
tion memory was found in 4-month-old and older mice
but not in younger animals (2 months). As shown
in Fig. 9A, 4-month-old mice spent approximately the
same time in the exploration of the new and the famil-
iar object with a discrimination index, DI = 0.55 ±
0.02, significantly lower (P < 0.001) than that of non-
transgenic mice, DI = 0.76± 0.02. No change in total
exploration time was observed in these two groups (not
shown)
Morris water maze. To assess spatial reference
learning and memory function, groups of 2- and 4-
month old hAβPPswe-ind mice and the corresponding
non-transgenic littermates (n = 12 per group) were
tested in the MWM. No cognitive deficits were found
in 2-month-old animals (not shown). In 4-month-
old mice, no significant difference in escape laten-
cy among groups was found during the days of vis-
ible platform training (Fig. 9B). In the spatial refer-
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of non-transgenic (Non-Tg) and transgenic hAβPPswe-ind mice. Values, means ± S.E.M. (n = 5–6), normalized according to β-actin levels,
are expressed as percentage of optical density (OD) of the corresponding Non-Tg mice. All experiments were performed in triplicate **P <
0.01 vs. non-transgenic mice (Student’s t test).
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Fig. 8. NMDA receptor subunit levels quantified by Western blot in membrane preparations from the hippocampus of 8-month-old non-transgenic
(Non-Tg) and transgenic hAβPPswe-ind mice. Values, means ± S.E.M. (n = 5–6), normalized according to β-actin levels, are expressed as
percentage of optical density (OD) of the corresponding Non-Tg mice. All experiments were performed in triplicate. Data are expressed as
relative change vs. non-transgenic littermates processed in parallel.
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Fig. 9. Behavioral analyses in hAβPPswe-ind mice. (A) Impaired memory in hAβPPswe-ind transgenic mice in the object recognition test
at different ages. The familiarization (T1) and choice (T2) sessions were spaced 24 h apart. Values are means ± S.E.M. (n = 19–32 in
non-transgenic (Non-Tg) and n = 11–19 in transgenic mice). ***P < 0.001 vs. Non-Tg mice (ANOVA followed by Sheffe t-test). (B) Escape
latency in the visible platform training of 4-month-old hAβPPswe-ind mice in the Morris water maze (MWM). (C) Escape latency in the invisible
platform in the MWM (*P < 0.05 vs Non-Tg, ANOVA followed by Student’s t test). (D) Impaired memory in hAβPPswe-ind mice in the three
15 s probe trials (*** P < 0.001, ANOVA followed by Student’s t test).
ence training (invisible platform), a mixed multifacto-
rial ANOVA analysis revealed a significant effect of
transgenic status on the MWM test performance (P <
0.05). hAβPPswe-ind mice showed escape latencies
significantly longer than non-transgenic littermates on
days 2–4 (Fig. 9C). It has been previously suggested
that the sensitivity of MWM test can be increased by
giving shorter probe trials [11], so we determined the
performance of mice during the first 15 s of every probe
trial. ANOVA revealed a significant effect of trans-
genic status in probe trials (P < 0.01). hAβPPswe-ind
mice did not retain a clear bias for the platform location
24 h after the last training session on days 4, 7 and 9
and spent less time in the correct quadrant of the pool
during every probe trial (P < 0.001) (Fig. 9D).
DISCUSSION
We found in AβPP transgenic mice an early decrease
in hippocampal EphA4 and EphB2 receptors that pre-
ceded an impaired object recognition and spatial mem-
ory. No change in surface expression of AMPA or
NMDA receptor subunits was found in hippocampal
membrane preparations at the time of onset of memory
decline. An increase in the membrane-associated ac-
tivity of cofilin, a downstream effector of Eph receptors
that could affect dendritic spine plasticity, was apparent
in the hippocampus at this time point. The reduction
found in p-PAK and p-LIMK levels may account for
the increased cofilin activity. The observed changes
suggest that early alterations in Eph receptor signaling
may contribute to the synaptic dysfunction previous
to synaptic loss in AD. Remarkably, reduced EphA4
and EphB2 levels were also found in postmortem hip-
pocampal sections from patients at an incipient stage
of AD.
Several biochemical signals regulate synaptic func-
tion and plasticity. Among them, ephrins and their
receptors are good candidates because of their impli-
cation in synaptogenesis, synaptic plasticity, memory,
regulation of excitatory neurotransmission, and reorga-
nization of cytoskeleton in the adult brain [9,12,40,41].
This reorganization is necessary for the spine remod-
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eling associated with the stabilization of learning and
memory [42]. Among the signals directly implicated in
actin cytoskeleton dynamics, the actin-depolymerizing
protein cofilin plays a crucial role [38]. It is known
that ephrins and their receptors modulate cofilin activ-
ity through their action on small GTPases proteins of
the Rho family, such as Rho A, Cdc42, and Rac, which
in turn modulate the activity of two key proteins impli-
cated in cofilin activation, PAK and LIMK [43]. When
PAK and/or LIMK activity is reduced, cofilin is activat-
ed and binds to actin to promote its depolymerization.
EphA4 receptors are highly expressed in brain struc-
tures with marked synaptic plasticity such as the hip-
pocampus [14], and electron microscopy studies have
shown that these receptors are basically localized on
dendritic spines of hippocampal pyramidal neurons as
well as on axon terminals [20,44]. Activation of EphA4
receptors is necessary for remodeling of CA1 dendritic
spines in processes of synaptic plasticity in the adult
brain [45–47], and EphA4 null mice have hippocampal
distorted spines, confirming that EphA4 is required to
maintain normal spine architecture in vivo [14,48]. An
early decrease in EphA4 receptor protein was found in
the hippocampus of hAβPPswe-ind mice, which may
account for the impairment in synaptic plasticity in this
brain region particularly vulnerable to degeneration in
AD. Some reports have shown that inactivation of EphA
receptors impairs performance of mice in behavioral
tasks [49,50]. It is conceivable that the early decrease
of EphA4 receptor levels found in mice overexpressing
mutant hAβPP, before the onset of cognitive deficits,
may affect the capacity to remodel the cytoskeleton
and also the instauration of plasticity changes associ-
ated with memory in these animals. The reduction of
EphA4 receptor levels was confirmed in another trans-
genic AβPP line, Tg2576 mice, before the onset of cog-
nitive decline which is not apparent in these mice until
they are 9–10 month-old, at least in the water-maze
test [32].
In regard to EphB2 receptor levels in the hippocam-
pus of hAβPPswe-ind mice, we found an early de-
crease of EphB2 receptors in 2-month-old animals with
no significant changes being observed at later ages (4–
8 months). A reduction in EphB2 receptor levels was
also found in Tg2576 mice at a single time point. It is
known that EphB receptor signaling regulates synap-
togenesis and dendritic spine morphogenesis and has
also been implicated in the development of excitato-
ry synapses [19,51,52]. The early decrease in hip-
pocampal EphB2 levels may consequently contribute to
impairing synaptic plasticity in hAβPPswe-ind mice.
EphB2 levels were not however reduced in 4- and 8-
month-old mice, but rather tended to be slightly in-
creased. The interpretation of the latter finding is un-
clear and may perhaps represent an attempt to com-
pensate for the subsequent synaptic dysfunction in
hAβPPswe-ind mice. In line with these results, a tran-
sient increase in EphB receptor expression within two
weeks of entorhinal deafferentation in mice has been
reported suggesting that, in addition to its role in synap-
tic plasticity in normal brain, EphB receptors may be
also involved in plasticity of the lesioned adult hip-
pocampus [53].
In both hAβPPswe-ind and Tg2576 mice, there is
an age-dependent cognitive decline, not only in spa-
tial memory but also in other learning and memory
tasks [31,32,54]. Transgenic mice do not recapitulate,
however, the full phenotype of AD. Even though these
mice are suitable for identification of therapeutic tar-
gets, a validation in brains from AD patients is neces-
sary. Interestingly, a decrease in EphA4 and EphB2 re-
ceptor levels was also found in postmortem hippocam-
pal sections from patients at a rather incipient stage of
AD. This finding obviously supports the possible role
of Eph receptor alterations in the pathogenesis of AD.
Among downstream effectors of Eph receptors
known to modulate actin cytoskeleton [13], a key
molecule is cofilin, an actin binding protein that crit-
ically controls cytoskeleton dynamics by enhancing
actin depolymerization [27]. Cofilin is inactivated by
phosphorylation at Ser3 so dephosphorylation of this
residue leads to cofilin activation and binding to actin
with the subsequent depolymerization and alterations
in the regulation of synaptic plasticity. It has been
reported that learning increases the number of spines
containing high concentrations of phosho-cofilin, also
an essential step in LTP [55]. A recent study showed
that EphA4 receptor reduces the association of cofilin
with the plasma membrane in heterologous cells and
organotypic hippocampal slices from non-transgenic
mice, suggesting a possible mechanism for the regu-
lation of synaptic structure through an EphA4 signal-
ing pathway [15]. In hAβPPswe-ind mice with a re-
duced EphA4 expression, we found however a small
decrease of cofilin in hippocampus membrane prepara-
tions. Obviously, this result, obtained from hippocam-
pal extracts of AβPP transgenic mice, cannot be strictly
compared with those of Zhou et al. [15] using heterolo-
gous cell or organotypic cultures. Our most significant
finding in this part of the study was the marked decrease
in phospho-cofilin(Ser3) in membrane hippocampal
preparations from 4-month-old hAβPPswe-ind mice,
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reflecting an activation of cofilin that may cause cy-
toskeletal changes and altered synaptic function. Re-
duced phospho-cofilin levels could be a consequence of
the early decrease found in the levels of phospho-PAK
and phospho-LIM-kinase, key enzymes in the nega-
tive regulation of cofilin activity [38,39]. Consistent
with the above findings, EphA4 receptor activation in
a neuroblastoma cell line markedly increased phospho-
cofilin levels, although the ligand used not only ac-
tivates EphA4 receptors but also the EphB receptor
class [42]. Our results agree with recent studies show-
ing that Aβ42 peptide induces dephosphorylation (ac-
tivation) of cofilin and formation of rod-shaped actin
bundles which may inhibit axonal transport, are sites
of AβPP accumulation and contribute to the patholo-
gy of AD [29,30]. Aβ oligomers induce a decrease in
spine density which seems to require active cofilin, so
prevention of cofilin activation by expressing a mutant
cofilin prevents the Aβ-induced spine loss. Controver-
sial findings, however, have been also reported. Here-
dia and colleagues [28] observed that Aβ-induced dys-
trophy requires LIM-kinase-mediated phosphorylation
of cofilin and, according to these authors, the difference
with the studies of Maloney et al. [30] may be related to
the Aβ dose or to the culture conditions. Furthermore,
it has been reported that cofilin signaling is perturbed
in AD brain tissue and active cofilin bound to actin was
found in pathological inclusions associated to AD [30,
56].
The critical role of excitatory neurotransmission in
the induction and maintenance of processes of synaptic
plasticity is well known. A dysfunction of the gluta-
matergic system has been found in AD [24] and, par-
ticularly, reduced surface amounts of NMDA and AM-
PA receptors have been reported in cultured neurons
from AβPP transgenic mice (see Introduction). Giv-
en the regulation of the glutamatergic system by Eph
receptors [19,57–60] and the early changes found in
hAβPPswe/ind mice, we analyzed the time-dependent
modification of AMPA receptor subunits in these trans-
genic mice. At early times (2–4 months) of pathology
progress, GluR1 and GluR2/3 levels were not altered
in hippocampal membranes. At a later time (8 months
of age), with histopathological abnormalities already
present, GluR1 subunit levels were decreased in hip-
pocampal membranes, a loss probably associated with
impaired synaptic plasticity [61,62]. This decrease
does not seem related to previous changes in Eph re-
ceptors because the localization of GluR2/3 subunits,
which may be modulated, among other factors, by
EphB2 receptors [58] was not modified. It is important
to note that these AβPP transgenic mice showed an ear-
ly (4 months of age) recognition and spatial memory
impairment without any change in membrane expres-
sion of AMPA receptors at this time point. The surface
expression of NMDA receptor subunits was not at all
modified, not even in 8-month-old animals.
In summary we found a decrease in EphA4 and
EphB2 receptor levels before the detection of mem-
ory decline in mice overexpressing mutant hAβPP.
These changes may account for modifications in cy-
toskeleton architecture, possibly associated with re-
duced phospho-cofilin levels, and for dynamic changes
affecting the correct instauration of synaptic plastici-
ty processes. The reported changes suggest an early
synaptic dysfunction in the hippocampus that, along
with other facts associated to hAβPP overexpression,
may lead to memory impairment in these transgenic
AβPP mice. The reduced EphA4 and EphB2 receptor
levels in postmortem hippocampal tissue from patients
at an incipient stage of AD support the hypothesis that
Eph receptors may represent a target for novel thera-
peutic strategies in AD.
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